Twist Bioscience Corporation (NASDAQ:TWST) on Monday reported a loss for its fiscal 2026 second quarter.
The life science company reported an adjusted loss of 59 cents, missing the consensus loss of 48 cents. The sales came in at $110.72 million, beating the consensus of $107.66 million, and the management guidance of $107 million-$108 million.
“We expect to chart toward profitability while simultaneously building on the strong momentum we are seeing across the portfolio. We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while holding gross margin above 52% for the fiscal year,” Emily Leproust, CEO and co-founder of Twist Bioscience.
Twist Bioscience raised its fiscal 2026 sales guidance from …
This post was originally published here
